Sudha Visvanathan

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study

Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease et al. · Arthritis & Rheumatism · 2009 · 603 citations

Medicine, Clinical Sciences, Pharmacotherapy +15

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial

Robert D. Inman, John C. Davis, Désirée van der Heijde et al. · Arthritis & Rheumatism · 2008 · 593 citations

Medicine, Clinical Sciences, Pharmacotherapy +7

Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.

Gary S. Hoffman, María C. Cid, Karen E. Rendt-Zagar et al. · PubMed · 2007 · 563 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Edward Keystone, Mark C. Genovese, Lars Klareskog et al. · Annals of the Rheumatic Diseases · 2008 · 541 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Josef S Smolen, Jonathan Kay, Mittie K. Doyle et al. · The Lancet · 2009 · 520 citations

Medicine, Clinical Sciences, Pharmacotherapy +12